IL6R overexpression

Additionally, the knockdown of miR-21 significantly inhibited the secretion of matrix metalloproteinases by CaSki cells. These results highlight that miR-21 could be a potential therapeutic target for cervical cancer, although further preclinical and clinical studies are required to validate its role and efficacy.

Background: The anti-CD38 monoclonal antibody daratumumab (Dara) significantly improves the outcomes of patients with multiple myeloma (MM). Overexpression of IL-6R in 1q+ MM leads to CD38 downregulation through the activation of the JAK/STAT pathway. This may be associated with the reduced efficacy of Dara in patients with 1q+ MM. Ruxolitinib and tocilizumab can potentially restore CD38 expression by suppressing this pathway, thereby enhancing the effects of Dara on 1q+ MM.

Together, our work demonstrates pro-tumorigenic traits of cGAS-STING signalling and explains why the cGAS-STING pathway is rarely inactivated in primary tumours. Repurposing tocilizumab could be a strategy to treat cancers with CIN that overexpress IL-6R.

miR-451a targeting IL-6R activates JAK2/STAT3 pathway, thus regulates the proliferation and apoptosis in MM cells.

Our results indicated that the cell migration and invasion were inhibited by knockdown of lncRNA NORAD or overexpression of miR-451, suggesting that the axis of lncRNA NORAD -miR-451- IL-6R was involved in the development of PTC.